Central Alerting System
View Alert

Originator: DHSC & NHS England and Improvement: Supply disruption alert

Issue date: 29-Sep-2020 16:42:35

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Specialists Trusts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Ambulance Trusts
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Mental Health & Learning Disabilities Trusts
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • Acute Trusts
  • Community Trusts
  • NHS Trusts (England) - Chief Executive
  • DHSC Supply Disruption - Medicines

Action category: Action

Title: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older) - Supply Disruption

Broadcast content:
An interim clinical commissioning policy has been in place since 3 July 2020, defining routine access to remdesivir in the treatment of COVID-19 across the UK, following confirmation of a Conditional Marketing Authorisation (CMA) by the European Medicines Agency (EMA).  

Due to increased demand against available supply, clinicians are now asked to apply the full eligibility criteria as set out within the associated Central Alerting System (CAS) alert CEM/CMO/2020/028(U), last published on 3rd September 2020, and listed below.

Clinicians are also asked to adhere to a standard treatment course of 5 days.

Given the links to covid-19 we have sent this alert to a broader mailing list than would usually receive a Supply Disruption Alert of this type.

Please note that no response is required via the CAS website to this alert.

Additional information: This alert is not relevant to Primary Care.

Alert reference: SDA/2020/013


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency